Back to News
Market Impact: 0.2
Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
Source: Business Wire
Healthcare & BiotechProduct Launches
Bristol Myers Squibb announced the first presentation of Phase 3 EXCALIBER-RRMM trial results for ZENBEXUS (iberdomide) combined with daratumumab in relapsed or refractory multiple myeloma. The headline provides no efficacy, safety, regulatory, or financial data, limiting immediate valuation implications.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
BMY0.55
More News
- Anthropic Goes Big on Compute, Microsoft Rethinks AI
- Wall Street Week | China’s Trade Reckoning, Syracuse’s Second Chance, Humanoids in Healthcare
- Yields keep rising, Novo's tough week, why cat product sales are surging and more in Morning Squawk
- Details on U.S.-China trade negotiations coming Monday, USTR Greer says
- Meta's 'powerful breakout' sets up a unique trading strategy, says Mike Khouw
- At Meta Connect, the company’s smart glasses were everywhere